Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis

URG101 Pharmacodynamic and Safety Study: A Randomized, Double-blind, Placebo-controlled, Multi-center Cross-over Study to Investigate the Pharmacodynamic Profile of URG101 in Subjects With Pelvic Pain of Bladder Origin.

A double-blind, placebo-controlled study to evaluate changes in pain, urgency and urinary frequency following administration of URG101 compared to placebo.

Inclusion Criteria:

• male and female subjects >= 18 years of age
• moderate to severe symptoms of PBS/IC
• minimum pain/urgency/frequency scores
• female subjects on hormone therapy must be on stable dose for >= 3 months

Exclusion Criteria:

• positive pregnancy test or pregnant or lactating
• narcotics or medical marijuana within 3 months
• use of any investigational drug or device within 30 days
• bacterial cystitis within 30 days